论文部分内容阅读
目的：探究EGCG与临床常用三联疗法对胞内幽门螺杆菌的抗菌活性进一步探究EGCG对临床常用疗法抗胞内幽门螺杆菌的活性的影响。方法利用AGS细胞建立幽门螺杆菌胞内感染模型,胞内活菌计数法测定胞内幽门螺杆菌数量。结果EGCG具有较强的胞内抗菌活性,临床常用抗Hp疗法不能有效清除胞内幽门螺杆菌,EGCG在其4~64 mg/L浓度范围内,能够明显增强临床常用抗Hp疗法的胞内抗菌作用。结论兰索拉唑+阿莫西林+莫西沙星具有较强的抗胞内幽门螺杆菌能力, EGCG能够在一定程度上增强临床常用疗法的抗胞内幽门螺杆菌能力,有望用于治疗胞内幽门螺杆菌感染。“,”Objective To explore the antibacterial activities of EGCG and the regular therapies and the influence of EGCG on the regular therapies against intracellular Helicobacter pylori.Methods Intracellular infection model of standard Helicobacter pylori was established using AGS cell.The viable count method was used to determine the intracellular Helicobacter pylori after cell rupture.Results EGCG demonstrates antibacterial activity against the intracellular Helicobacter pylori and the regular therapies cannot eliminate the intracellular Helicobacter pylori EGCG obviously increased the activities of the regular therapies against intracellular Helicobacter pylori within 4~64mg/L. Conclusion The MXF-LAN-AMX combination demonstrates a greate ability EGCG can enhance the activities of the three regular therapies against intracellular Helicobacter pylori and may be used to treat the clinical infection of intracellular Helicobacter pylori.